

Assessing payment adequacy: outpatient dialysis services

Nancy Ray December 15, 2011



Background

- Outpatient dialysis services used to treat individuals with end-stage renal disease
- Agenda
 - Overview of modernized payment method
 - Payment adequacy analysis



Key features of the new PPS

Expands the payment bundle

- Composite rate services
- Part B dialysis drugs and their oral equivalents
- ESRD-related laboratory services
- Selected Part D drugs
- Adjusts for beneficiary characteristics
 - Age and body mass
 - 3 chronic and 3 acute comorbidities
 - Dialysis onset

MECIPAC

Key features of the new PPS

- Adjusts for low volume
 - Based on total number of treatments
- Includes an outlier policy
 - Portion of bundle that was previously separately billable
- Provides for a four-year transition
- Applies budget-neutrality adjustment
 - MIPPA: 2 percent reduction in 2011



Key features of the new PPS

- Annually updates the payment rate
 - Implemented by MIPPA, modified by PPACA: market basket less productivity factor
- Links payment to quality
 - Medicare's first quality incentive program
 - 2 percent withhold
 - Will begin in 2012 using 1 measure on dialysis adequacy and 2 measures on anemia management



Issues with new PPS

- Use of drugs under a bundled payment method
 - Lower volume in 2010; industry data suggests volume decreases in 2011
- P4P measures in 2013 and 2014 do not hold providers accountable for outcomes associated with the under-provision of dialysis drugs
- Design of the low volume adjuster does not consider the distance to the nearest facility



Payment adequacy factors

Beneficiaries' access to care
Supply and capacity of providers
Volume of services
Changes in the quality of care
Providers' access to capital
Payments and costs



Capacity growing for freestanding, chain, and for profit facilities

| | No. of facilities in 2011 (percent) | Avg. annual growth since 2006 | Growth since 2010 |
|------------------------------|---|-------------------------------------|----------------------|
| All | 5,560 (100%) | 4% | 3% |
| Freestanding | 5,010 (90%) | 5% | 4% |
| Hospital-based | 550 (10%) | –2% | 4% |
| Affiliated with LDOs | 3,433 (62%) | 4% | 5% |
| Affiliated with other chain | 1,086 (20%) | 8% | 5% |
| Not affiliated with chain | 1,041 (19%) | 0.2 | —4% |
| For profit | 4,619 (83%) | 5% | 4% |
| Nonprofit | 941 (17%) | 0.2% | -2% |
| Urban | 4,352 (78%) | 4% | 3% |
| Rural micropolitan | 755 (14%) | 4% | 3% |
| Rural, adjacent to urban | 281 (5%) | 5% | 3% |
| Rural, not adjacent to urban | 172 (3%) | 4% | 3% |

Data are preliminary and subject to change.

MECPAC

Beneficiaries' access to care

- The number of dialysis stations has kept pace with the growth in the number of all dialysis patients
- Few facility closures in 2009—linked to size and profitability
- Closures did not disproportionately affect patients based on age, sex, and race




Change in volume for dialysis treatments

The number of dialysis FFS patients has kept pace with the growth in the number of all dialysis treatments

| | | | | Annual Growth | |
|-----------------------------|------|------|------|---------------|-----------|
| | 2005 | 2009 | 2010 | 2005-2010 | 2009-2010 |
| FFS patients (in thousands) | 320 | 343 | 357 | 2% | 4% |
| Treatments (in millions) | 35.3 | 38.8 | 40.6 | 3 | 5 |

Data are preliminary and subject to change.


Change in erythropoietin use in 2010



Source: MedPAC analysis of mean dose per week using 2010 erythropoietin claims submitted by freestanding facilities. Data are preliminary and subject to change.



Dialysis quality is high or improving for some measures



Data are preliminary and subject to change.

MECIPAC

Quality improvements are still needed for other clinical measures and outcomes

- Nutritional status
- Phosphorous and calcium management
- Rates of hospitalization
- Rates of mortality
- Proportion of patients registered on the kidney transplant list and rate of kidney transplantation



Providers' access to capital

- Increasing number of facilities that are forprofit and freestanding
- Large and small freestanding chains have similar growth in capacity
- Both large and small chains have access to private capital to fund acquisitions



2010 Medicare margin

| Type of freestanding provider | Percent of spending by freestanding dialysis facilities | Medicare margin |
|--|---|--------------------|
| All | 100% | 2.3% |
| Affiliated with 2 largest dialysis chains Not affiliated with 2 largest dialysis chains | 69% 31% | 3.4% 0.1% |
| Urban Rural | 85% 15% | 3.4% -3.7% |
| Provided: > 10,000 treatments ≤ 10,000 treatments | 46% 54% | 7.7% –2.3% |

2010 Medicare margin includes payments and costs for composite rate services and dialysis drugs.



Data are preliminary and subject to change.